Clinical Study of KW-2246 in Patients With Cancer Pain
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study is a Phase II open-label study to investigate the recommended conversion ratio
(oral morphine dose to KW-2246) when switching oral morphine or oxycodone to KW-2246 in
cancer patients.
Phase:
Phase 2
Details
Lead Sponsor:
Kyowa Hakko Kirin Company, Limited Kyowa Kirin Co., Ltd.